Ethan Basch

Oncologist, Cancer Outcomes Researcher, Bass Player

[Ethan Basch @EthanBasch1]

On this US Labor Day, I feel gratitude for the many dedicated @UNC_Health_Care and @UNC_Lineberger staff supporting patients with cancer, particularly after 2+ tough years with staffing shortages and Covid absences. Thank you.

[Mel Calvert @drmelcalvert]

New models of working for #clinical trials? Patient-informed investigator reporting of adverse events @EthanBasch1 @BiostatGirl #OCEoutcomes22 @FDAOncology - love this approach! @NIHRBhamBRC

[Robert S Miller, MD, FACP, FASCO, FAMIA-he/him @rsm2800]

Great to see this impt work out in JAMA & honored to contribute on behalf of @ASCO. Congrats to @EthanBasch1 & all co-authors 👉🏻 Electronic Symptom Monitoring With Patient-Reported Surveys and Outcomes Among Patients With Metastatic Cancer https://t.co/iUi0FsdjuB #PRO #HRQOL

[Ryan Nipp, MD, MPH, MBA, FASCO @RyanNipp]

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic #Cancer.

https://t.co/vkNkZbB88K

@ASCO @JAMA_current @EthanBasch1 @BiostatGirl
#PallOnc #PROs #DigitalHealth #ASCO22

[ASCO @ASCO]

#ASCO22 TOMORROW: Join presenters from the #ASCOPlenarySeries for ⚡ rapid abstract updates on their research, followed by a panel q&a moderated by @GeorgeSledge51 & @KimmieNgMD 

📅 6/5, 4:30 – 6:00 PM CT
📌 Arie Crown Theater & Online

@EthanBasch1 @GistLab @ProfGLongMIA

[Ethan Basch @EthanBasch1]

Excited to present at #ASCO22, the PRO-TECT multicenter randomized trial of a PRO digital tool for symptom monitoring in US oncology practices, with simultaneous publication in JAMA @JAMA_current, in the ASCO Plenary Series update session, 6/5/22 5:30pm EDT. @ALLIANCE_org @PCORI

[Ethan Basch @EthanBasch1]

@drmelcalvert @JAMA_current The pleasure was all mine! Many thanks Dr. Calvert for this superb work.

[The Sato Lab (Kei Sato) @SystemsVirology]

Our pre-preprint has been uploaded (free available from the URL below). It will be come out as a preprint (and hopefully a peer-reviewed paper) pretty soon.
And yes, we are G2P-Japan🇯🇵
Happy Xmas🎄 5/5

https://t.co/k04qQG97ZB

[The Sato Lab (Kei Sato) @SystemsVirology]

Moreover, our statistical analysis shows that Omicron is >3-5-fold more transmissible than Delta. 4/5

[The Sato Lab (Kei Sato) @SystemsVirology]

In sharp contrast, Omicron is less fusogenic (left panel) and its spike is faintly cleaved (right panel). Our data suggest that the efficacy of spike protein cleavage, fusogenicity and pathogenicity are well correlated each other. 3/5

[The Sato Lab (Kei Sato) @SystemsVirology]

How come?
We have recently reported that Delta spike is efficiently cleaved into two subunits, and therefore, Delta is highly fusogenic and highly pathogenic @Nature . 2/5
https://t.co/xAQb9Zu6ns

[The Sato Lab (Kei Sato) @SystemsVirology]

BREAKING🎄 The 6th preprint from G2P-Japan - #Omicron is less infectious and pathogenic than #Delta and even an early pandemic SARS-CoV-2 in infected hamster model. 1/5

[Annals of Oncology @Annals_Oncology]

New #COVID19 🦠 #openaccess resource in Annals of Oncology: COVID-19 Vaccination 💉 and Breakthrough Infections in Patients with Cancer
➡️ https://t.co/G1GpTGJ3oK

@COVID19nCCC @DrChoueiri

[ACS Journal Cancer @JournalCancer]

Adolescent and young adult patients w/ #cancer are well-represented in @theNCI #ClinicalTrials and are more racially/ethnically diverse than older patients https://t.co/8hfHVuhd3s @SWOG @fredhutch @DrJoeUnger @DrDawnHershman

[ASCO @ASCO]

News from #ASCOPlenarySeries: Digital Symptom Monitoring With PROs in Community Practices Improves Patient QoL via @TargetedOnc @Sara_Karlo7 https://t.co/p4tVy89ai5 @EthanBasch1 #medtech #digitalhealth #ePROs

[Toni Choueiri, MD @DrChoueiri]

Looking forward for the inaugural #ASCOPlenarySeries from @EthanBasch1 @UNC_Lineberger -Digital symptoms monitoring in the oncology community: a randomized trial! @ASCO @ASCOPres @jrgralow @CliffordHudis @MLJohnsonMD2 @GeorgeSledge51

[Arlene Chung, MD, MHA, MMCi, FAMIA @arlenechung]

Nice to collaborate w/@gitamody on this impt paper! ePRO monitoring during lung cancer tx not only feasible but identified severe sxs https://t.co/fIxsIDJNVf @Angela_M_Stover @angiesmith_uro @EthanBasch1 @arlenechung @bennettphd @BiostatGirl @debschrag @BellKingKal

[Ethan Basch @EthanBasch1]

@MassimoDiMaio75 @BiostatGirl @drmelcalvert @marialuciareale Agree @MassimoDiMaio75 — here’s an example of such an analysis https://t.co/fFKIEL17UF

[Ethan Basch @EthanBasch1]

@BiostatGirl @drmelcalvert @MassimoDiMaio75 This is an important paper for PRO use in cancer drug development, laying to rest the fallacy that unblinding of treatment allocation in controlled or single arm trials affects PRO responses - it DOESN’T. Key for @FDAOncology to acknowledge and encourage PROs in all applications.

[Paul Kluetz @pkluetz]

Just kicked this years workshop off and excited to hear @vishalbmd and @EGHorod lead some interesting sessions on physical function! How can we analyze and describe physical function for patients receiving an anti-cancer treatment? #OCEOutcomes21